New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
11:03 EDTDDD, SSYS, VJET, XONE, GE, SYK, JNJ3D printer makers tumble after profit warning from 3D Systems
Shares of 3D printer makers are sinking after the largest company in the sector in terms of market capitalization, 3D Systems (DDD), pre-announced lower than expected fiscal 2013 profit and gave a disappointing earning outlook for next year. WHAT'S NEW: 3D Systems reduced its fiscal 2013 earnings per share outlook to 83c-87c from 93c-$1.03. Analysts' consensus estimate was 96c. However, the company reported preliminary fiscal 2013 revenue of $513 million-$514 million, within its previous outlook of $500M-$530M. Analysts' consensus estimate was $514.24M. 3D Systems blamed its lower than expected fiscal 2013 EPS on "very significant R&D, manufacturing and marketing investments designed to accelerate revenue growth," along with weaker than expected demand for its parts and consumer products. For fiscal 2014, 3D Systems predicted that its EPS would be 73c-85c, versus analysts' consensus estimate of $1.27. However, the 3D printer maker expects its fiscal 2014 revenue to come in at $680M-$720M, versus the consensus estimate of $671.29M. ANALYST REACTION: In a note to investors earlier today, Jefferies analyst Peter Misek wrote that 3D Systems' opportunity in the professional and industrial markets is "only just beginning." 3D Systems' guidance is "appropriately conservative," wrote Misek, adding that his research suggests that the 3D printer maker is likely to announce deals with at least three major companies in 2014: Stryker (SYK), Johnson & Johnson (JNJ), and GE (GE). Misek kept a Buy rating on the stock. PRICE ACTION: In mid-morning trading, 3D Systems tumbled 22% to $59.25, but the stock was well above its low for the day of $54.63. Likewise, another major 3D printer maker, Stratasys (SSYS), retreated 8% to $108.60, but was well off its low for the day of $102.20. Another company in the space, ExOne (XONE), sank 10% to $40.27, while European 3D printer maker Voxeljet (VJET) gave back 6% to trade near $32.
News For DDD;SSYS;VJET;XONE;GE;SYK;JNJ From The Last 14 Days
Check below for free stories on DDD;SSYS;VJET;XONE;GE;SYK;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 15, 2014
09:46 EDTGEGE's FES selected by SpiceJet Airlines to support entire fleet
SpiceJet Airlines has selected GE’s (GE) Flight Efficiency Services to support its fleet of 52 Boeing (BA) 737 and Bombardier Q400 aircraft. GE will provide flight data analytics and fuel management to optimize the airline’s operational efficiency with the goal of substantially reducing fuel expenses for the airline. GE will provide consultation and evaluation services with the aim of reducing the airline’s fuel consumption and carbon emissions. GE is also designing and implementing custom solutions for SpiceJet and performing on-going efficiency measurements.
09:36 EDTJNJJohnson & Johnson sees FY14 pre-tax op. margin improving over FY13
Subscribe for More Information
09:30 EDTJNJJohnson & Johnson says will buy back shares with net gain from OCD divestiture
Subscribe for More Information
09:28 EDTJNJJohnson & Johnson sees 2014 sales $74.5B-$75.3B, consensus $74.91B
Subscribe for More Information
09:07 EDTSSYSStratasys initiated with an Outperform at Cowen
Subscribe for More Information
08:54 EDTJNJJ&J CEO says confident about long term growth prospects of healthcare market
Subscribe for More Information
08:25 EDTJNJJohnson & Johnson says innovation sustaining long-term growth
Says MD&D progressing well towards 30 major filings by 2017. In Pharmaceuticals, sees 10 new products and 25 significant line extensions planned by 2017. Sees ~4.5% CAGR expected for WW prescription drug sales through 2017, despite potential headwinds. Comments from slides that will be presented on the Q2 earnings conference call.
07:49 EDTJNJJohnson & Johnson reports Q2 Worldwide Pharmaceutical sales of $8.5B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson raises FY14 EPS to $5.85-$5.92 from $5.75-$5.85
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson reports Q2 Domestic sales up 14.9% to $9.13B
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q2 EPS excluding items $1.66, consensus $1.55
Subscribe for More Information
06:50 EDTGEGE anticipates meeting $30B air show goal, Reuters says
Subscribe for More Information
July 14, 2014
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
09:06 EDTGEEmirates signs $13B GE9X services agreement
Subscribe for More Information
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
07:58 EDTSSYSMakerBot, Home Depot to bring MakerBot 3D printers to select stores
MakerBot, a subsidiary of Stratasys (SSYS), and The Home Depot (HD) announce a collaboration to bring MakerBot Replicator Desktop 3D Printers to customers on homedepot.com/makerbot and in 12 Home Depot stores in California, Illinois and New York beginning July 14. This is the first time The Home Depot has offered 3D printers for sale in its stores and will be a pilot program for MakerBot and The Home Depot.
07:43 EDTGEGE far ahead of Caterpillar in race for cleaner diesel train, WSJ says
Caterpillar (CAT) has fallen far behind in the race to offer a locomotive that meets stricter emission standards taking effect next year, with its Electro-Motive Diesel unit stating that its freight trains probably won't be available until 2017, while General Electric (GE) is already testing trains that comply with the new rules, reported The Wall Street Journal. Reference Link
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use